tetano
Editor, Senior Moderator
Diagnostics (Basel)
. 2021 Oct 27;11(11):1998.
doi: 10.3390/diagnostics11111998.
Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19
Leticia Alserawan[SUP] 1 [/SUP], Patricia Peñacoba[SUP] 2 [/SUP], Sandra Elizabet Orozco Echevarría[SUP] 2 [/SUP], Diego Castillo[SUP] 2 [/SUP], Esther Ortiz[SUP] 1 [/SUP], Laura Martínez-Martínez[SUP] 1 [/SUP], Esther Moga Naranjo[SUP] 1 [/SUP], Pere Domingo[SUP] 3 [/SUP], Ivan Castellví[SUP] 4 [/SUP], Cándido Juárez[SUP] 1 [/SUP], Anaís Mariscal[SUP] 1 [/SUP]
Affiliations
Abstract
It is essential to find new biomarkers for severity stratification of patients with coronavirus disease (COVID-19). Growth differentiation factor 15 (GDF-15) is upregulated in pathological conditions that involve inflammation and/or oxidative stress. We determined circulating levels of GDF-15 and correlated them with clinical and laboratory parameters reflecting severity in 84 patients with COVID-19, finding that GDF-15 levels were higher in both patients than in 20 healthy controls and were higher in patients with poorer respiratory function. GDF-15 levels also correlated with interleukin-6, C-reactive protein, ferritin and D-dimer levels and with neutrophilia and lymphopenia. Of all the analysed biomarkers, GDF-15 showed the best area under the receiver operating characteristics curve in identifying patients with poor respiratory function. In conclusion, our data support GDF-15 as a biomarker associated with pulmonary impairment in COVID-19 and so can potentially be useful in stratifying COVID-19 cases by severity.
Keywords: COVID-19; GDF-15; biomarker; inflammation; respiratory function.
. 2021 Oct 27;11(11):1998.
doi: 10.3390/diagnostics11111998.
Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19
Leticia Alserawan[SUP] 1 [/SUP], Patricia Peñacoba[SUP] 2 [/SUP], Sandra Elizabet Orozco Echevarría[SUP] 2 [/SUP], Diego Castillo[SUP] 2 [/SUP], Esther Ortiz[SUP] 1 [/SUP], Laura Martínez-Martínez[SUP] 1 [/SUP], Esther Moga Naranjo[SUP] 1 [/SUP], Pere Domingo[SUP] 3 [/SUP], Ivan Castellví[SUP] 4 [/SUP], Cándido Juárez[SUP] 1 [/SUP], Anaís Mariscal[SUP] 1 [/SUP]
Affiliations
- PMID: 34829345
- DOI: 10.3390/diagnostics11111998
Abstract
It is essential to find new biomarkers for severity stratification of patients with coronavirus disease (COVID-19). Growth differentiation factor 15 (GDF-15) is upregulated in pathological conditions that involve inflammation and/or oxidative stress. We determined circulating levels of GDF-15 and correlated them with clinical and laboratory parameters reflecting severity in 84 patients with COVID-19, finding that GDF-15 levels were higher in both patients than in 20 healthy controls and were higher in patients with poorer respiratory function. GDF-15 levels also correlated with interleukin-6, C-reactive protein, ferritin and D-dimer levels and with neutrophilia and lymphopenia. Of all the analysed biomarkers, GDF-15 showed the best area under the receiver operating characteristics curve in identifying patients with poor respiratory function. In conclusion, our data support GDF-15 as a biomarker associated with pulmonary impairment in COVID-19 and so can potentially be useful in stratifying COVID-19 cases by severity.
Keywords: COVID-19; GDF-15; biomarker; inflammation; respiratory function.